

2025 GENERAL MEETING

CHANGE OF MEETING VENUE

Memphasys Limited (ASX: MEM) a biotechnology company focused on developing and commercialising innovative products for assisted reproduction advises that the venue for holding the General Meeting on Friday 8 August 2025 commencing at 10am (Sydney time) is now to be held in the main boardroom at:

Level 32/200 George Street

The General Meeting is being held as a physical meeting of shareholders, therefore any member wishing to vote can do so by lodging their proxy form no later than 48 hours prior to the meeting or attend and vote at the meeting in person. Other than the address/location all the details in the notice of meeting released to the market on 8 July 2025 remain unchanged.

Questions can also be submitting in advance of the Meeting by emailing the questions to Company Secretary by no later than 5.00pm (Sydney time) on Wednesday 6 August 2025 at info@memphasys.com

Authorised by the Board of Memphasys Limited.

Ends

For further information, please contact:

Dr. David Ali
Managing Director & CEO
Memphasys Limited
Tel: +61 2 8415 7300
E: david.ali@memphasys.com

Andrew Metcalfe
Company Secretary
Tel: +61 3 9867 7199
E: andrew@accosec.com

About Memphasys Limited

Memphasys Limited (ASX: MEM) specialises in advanced reproductive biotechnology, developing medical devices, diagnostics, and proprietary media for human and animal applications. With flagship technologies like the Felix™ and RoXsta™ Systems, Memphasys is committed to delivering transformative solutions that enhance fertility outcomes worldwide.

Website: www.memphasys.com